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Abstract
Background: Prognostic markers and molecular breast cancer subtypes reflect underlying biological tumor
behavior and are important for patient management. Compared to Western countries, women in North Africa are
less likely to be prognosticated and treated based on well-characterized markers such as the estrogen receptor
(ER), progesterone receptor (PR) and Her2. We conducted this study to determine the prevalence of breast cancer
molecular subtypes in the North African country of Egypt as a measure of underlying biological characteristics
driving tumor manifestations.
Methods: To determine molecular subtypes we characterized over 200 tumor specimens obtained from Egypt by
performing ER, PR, Her2, CK5/6, EGFR and Ki67 immunohistochemistry.
Results: Our study demonstrated that the Luminal A subtype, associated with favorable prognosis, was found in
nearly 45% of cases examined. However, the basal-like subtype, associated with poor prognosis, was found in 11%
of cases. These findings are in sharp contrast to other parts of Africa in which the basal-like subtype is over-
represented.
Conclusions: Egyptians appear to have favorable underlying biology, albeit having advanced disease at diagnosis.
These data suggest that Egyptians would largely profit from early detection of their disease. Intervention at the
public health level, including education on the benefits of early detection is necessary and would likely have
tremendous impact on breast cancer outcome in Egypt.
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Background
The World Health Organization has ranked breast can-
cer as the most common type of cancer among women
world-wide [1]. The incidence rates of breast cancer
vary worldwide, with higher rates in North America,
Northern and Western Europe; intermediate rates in
South America and Southern Europe; and lower rates in
Africa and Asia. According to GLOBOCAN 2008 [1]
breast cancer accounts for 38% of all new cancer cases
among women living in Egypt. The age-standardized
rate (ASR) for breast cancer incidence in Egypt is 37.3
compared to 76 in the United States. Although inci-
dence remains significantly lower than in highly devel-
oped countries, rates are steadily increasing [2,3].
Mortality rates in Egypt are worse (20.1 per 100 000)
then they are in the United States (14.7 per 100 000),
and is the leading cause of cancer-related deaths.
There is evidence that the global burden of cancer is
shifting gradually to the developing world, and may
equally affect or even surpass that of Western societies
within the foreseeable future [1]. Despite this shift,
breast cancer research in Africa comprises less than 1%
of the literature as indexed in the National Library of
Medicine database (PUBMED). The bias that little can
be done to affect the course of third world women dis-
ease, the lack of objective measureable data and the
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absence of evidence-based medicine thwart the ability of
clinicians to effectively manage cancer and guide health
policies in Africa.
Breast cancer is a heterogeneous disease composed of a
number of recognizable histological and intrinsic mole-
cular subtypes [4-6]. The molecular subtypes, based on
gene expression profiles, reflect underlying biological
behavior of tumors and differ markedly in prognosis
[4-6]. Intrinsic subtypes include two main subtypes:
Estrogen-receptor (ER) positive (+) tumors (termed
Luminal A and B) and ER negative (-) tumors (basal-like
and human epidermal growth factor receptor-2-positive
(Her2+) [4-6]. Luminal A and Luminal B subtypes are
known to be associated with better prognostic features
including low proliferative index, low histologic grade,
and a tendency towards smaller tumors. However, com-
pared to Luminal A tumors, Luminal B tumors are
reported to have higher proliferation and poorer prog-
nosis [7]. The basal-like subtype has been associated with
the worst prognosis, clinical characteristics and amen-
ability to available treatment options [5]. Molecular clas-
sifications are based on expression data from fresh-
frozen samples, which are not normally prepared in third
world countries. Therefore, surrogate markers based on
protein expression in formalin-fixed, paraffin-embedded
(FFPE) tissues are used that can predict the underlying
molecular basis of breast cancer; along with the conse-
quential prognosis and therapeutic choices of clinicians.
Currently little is still known regarding the molecular
characteristics contributing to the significantly high
mortality rates in regions like North Africa, including
Egypt. The objective of the current study was to deter-
mine the prevalence of breast tumor molecular subtypes
in an Egyptian population sampling to determine the
underlying biological characteristics driving tumor mani-
festations in Egypt. In our study, we performed immu-
nohistochemical analysis using the widely accepted
surrogate markers that have been previously verified
against gene expression profiles to accurately define the
prevalence of intrinsic subtypes in our population
cohort [8,9]. Such a survey will provide significant
insight into underlying biological characteristics that
may be predominating in a disparate patient population
with seemingly aggressive tumor pathology and clinical
progression. In light of minimal resources available in
Africa, this work will guide future efforts in the region
to determine whether an emphasis needs to be placed
on biological variability or health disparities and socio-
economic/cultural factors.
Methods
Sample Collection
Archival materials from 359 patients with confirmed
breast cancer diagnosis were obtained from the
University of Cairo, Faculty of Medicine, and the Uni-
versity of Minia, Faculty of Medicine in Egypt under
appropriate institutional ethical review board approval.
All samples were reviewed and verified by a board certi-
fied pathologist in each center (EH and SG). These sam-
ples represent a homogenous population comprising
samples from urban (Cairo: n = 159) and rural (Minia: n
= 200) areas. Samples were FFPE according to routine
surgical pathology practices and collected between 2003
and 2008. Re-embedding of tissue was performed when
necessary. All tumors were graded in Egypt according to
the Nottingham criteria [10-12]. Pathologic features
including histologic diagnosis, grade, tumor size, regio-
nal lymph node metastases as well as patient age and
type of surgery performed were extracted from the
pathology reports wherever possible. Although Notting-
ham criteria was used to stage tumors (low grade = G1,
intermediate grade = G2 and high grade = G3), tumor
size was categorized according to the American Joint
Committee on Cancer T classification: T1: tumor ≤ 2.0
cm; T2: tumor > 2.0 cm, ≤5.0 cm; T3: tumor > 5.0 cm.
T4 tumor category was excluded because of missing
clinical data as, for example, presence of edema or
extension to chest wall. Patients with at least one regio-
nal lymph node metastasis were considered lymph node
positive.
Construction of Tissue Microarray (TMA),
Immunohistochemistry and Semi-quantitative analysis
To identify areas of invasive breast cancer whole sec-
tions were stained with hematoxylin and eosin and eval-
uated by trained pathologists (JR and CT). Four 1.5 mm
cores from each FFPE tumor block were precisely
arrayed into a new recipient paraffin block using a tissue
micro-array system (Beecher Instruments, Silver Spring,
MD).
Immunohistochemistry (IHC) for ER, PR, Her2, Ki67,
EGFR and cytokeratin (CK) 5/6 was performed on
sequential sections using referenced methods. Briefly,
ER and PR staining was done with pre-diluted monoclo-
nal mouse antibodies (DAKO K1904, Carpentaria, CA)
after antigen retrieval with citrate buffer (pH 6) for
approximately 45 minutes (cat# 760-107, Ventana, Tuc-
son Arizona). Detection of Her2 and EGFR was achieved
with a rabbit polyclonal anti-Her2 antibody (1:100 dilu-
tion, DAKO, cat# A0485) or a mouse monoclonal anti-
EGFR antibody (prediluted, Ventana, clone 3C6) after
antigen retrieval with citrate buffer as above. ER, PR,
Her2 and EGFR antibodies were incubated for 32 min-
utes at room temperature. Antigen retrieval for Ki67
was performed with EDTA/borate/tris buffer (pH 8) for
45 minutes. Slides were incubated with a 1:50 dilution
of the Ki67 antibody (Abcam, cat# 833-500) for 1 hour
at room temperature. CK 5/6 staining was conducted
Salhia et al. BMC Women?’?s Health 2011, 11:44
http://www.biomedcentral.com/1472-6874/11/44
Page 2 of 9
with a monoclonal antibody (Dako, cat# IS780, 1:75) for
1 hour at room temperature after citrate buffer antigen
retrieval for 45 minutes. Staining was visualized using
the 3, 3-diaminobenzadine chromagen kit (Ventana, cat#
760-124) and hematoxylin counterstain. Appropriate
negative controls for immunostaining were prepared by
omitting the primary antibody step. Slides were pre-
pared and stained with a Ventana Discovery XT auto-
mated immunostainer (Ventana) according to
manufacturer’s instructions.
The results of the immunostaining were scored semi-
quantitatively by one pathologist (CT). ER and PR positivity
were defined as any positive nuclear staining (i.e. ≥ 1%).
Her2 was scored from 0 to 3; 0 = no staining; a score of 1 =
faint, partial staining of the membrane; a score of 2 = weak
complete staining of the membrane in > 10% of cancer
cells; a score of 3 = intense complete staining of the mem-
brane in > 10% of cancer cells. Her2 positive cases were
defined as IHC scores greater than ≥2. CK 5/6 positivity
was defined by any degree of cytoplasmatic staining in the
tumor cells. EGFR was considered positive if any membra-
nous staining was detectable. For Ki67, percent positive
nuclei of tumor cells was estimated by CT. Ki67 positivity
was defined as staining in greater than 1% of tumor cells.
Consistent with criteria developed from peer reviewed
publications, the combinations of IHC markers used to
define breast cancer molecular subtypes were as follows:
Luminal A (ER positive and/or PR positive, Her2 negative,
Ki67 low), Luminal B (ER positive and/or PR positive,
Her2 positive and/or Her2 negative/Ki67 high), Her2
+/ER- (ER negative, PR negative, Her2 positive), basal-like
(ER negative, PR negative, Her2 negative, EGFR positive
and/or CK5/6 positive), and unclassified (ER negative, PR
negative, Her2 negative, EGFR negative and CK5/6 nega-
tive). Tumors were excluded from the study for the follow-
ing reasons: missing tissue spots within the TMA, absence
of invasive carcinoma, negative staining for all six markers
and if scores could not be obtained for each marker being
analyzed due to missing spots on a sequential array.
Statistical Analysis
Patient and tumor characteristics were compared across
breast cancer subtypes using the Chi-square (c2) test for
categorical variables. One-way and two-way analysis of
variance (ANOVA) and the Kruskal-Wallis test were used
for continuous variables. All statistical analyses were per-
formed on GraphPad Prism version 5 (La Jolla, CA).
Results
A total of 203 cases with invasive breast cancer were ulti-
mately included in the study. Of these, 90 (44%) were
obtained from Cairo and 113 (55.6%) were obtained from
Minia (Table 1). Tables 1, 2 and 3 summarize the clinic-
pathological characteristics of the study cohort by five
molecular subtypes. The mean age was 51.3 years for all
cases, and 46.5% were older than 50 years of age. Age was
evenly distributed between sites (Table 2). Breast cancer
from male patients comprised 2.5% (n = 5) of samples
analyzed (Table 2). Over 70% of patients had positive
regional lymph node metastases and/or tumors > 2.0 cm
in size (≥T2, Table 3). Tumors were either intermediate
grade (82.2%) or high grade (17.1%) and virtually none
were low grade (G1) tumors (Table 3). The majority of
cases (75.5%) were histologically ductal carcinomas.
Medullary carcinomas represented 9.0% of tumors, which
is higher than generally seen in the West (Table 3). There
were site-specific differences for some clinical-pathological
features. In our cohort, 81% of tumors from Minia were
lymph node positive compared with 61% from Cairo (p =
0.0029, Table 4). Interestingly 25.7% of tumors in Minia
were categorized as T1, significantly (p < 0.001) more than
seen in the Cairene population (6.1%, Table 4). There was
an association of histological grade whether tumors origi-
nated from Minia or Cairo (p < 0.0001, Table 4). Thirty
percent of tumors from Minia were high grade (G3) com-
pared with only 4.1% in Cairo. About 95% of tumors from
Cairo were intermediate grade (G2) compared to only 70%
in Minia (Table 4). The distribution of histological type
was equal between sites (data not shown).
Prevalence of molecular subtypes
The 203 tumors fell into one of five molecular sub-
groups based on IHC criteria described above (Table 1).
Overall, IHC analysis revealed that 65.0% 43.8% and
25.1% were positive for ER, PR and Her2, respectively
(Table 5). We used IHC scores ≥2 to define HER2
Table 1 Distribution of molecular subtypes by site of origin
Total Tissue Cases
(N = 203)
Luminal A
(N = 90)
Luminal B
(N = 50)
HER+/ER-
(N = 24)
Unclassified
(N = 16)
Basal-like[CK5/6]
(N = 23)
p-value
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Percent of Tissue Cases 100.0% 44.3% 24.6% 11.8% 7.9% 11.3%
Site * * * * < 0.0001
Cairo, Egypt 90 (44.3%) 39 (43.3%) 20 (40.0%) 10 (41.7%) 13 (81.3%) 8 (34.8%)
Minia, Egypt 113 (55.7%) 51 (56.7%) 30 (60.0%) 14 (58.3%) 3 (18.8%) 15 (65.2%)
Asterisk (*) represents groups with statistically significant differences.
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positive tumors. Although a potential limitation of our
study is the lack of HER2 FISH to accurately call Her2
positive tumors with IHC scores of 2+, our maximum
false negative rate is 2% for our dataset. Furthermore,
evidence is emerging that women with intermediate
IHC scores of 2+ without amplification by HER2 FISH
may also benefit from trastuzumab therapy [13]. The
incidence of ER (p = 0.13), PR (p = 0.09) and Her2 (p =
0.51) positivity was nearly the same between Minia and
Cairo (Table 5). The majority of tumors were Luminal
A (44.3%), 24.6% were Luminal B and less than 12%
were Her2+/ER-, unclassified or basal-like (Figure 1,
Table 1). The distribution of Luminal A and Her2+/ER-
subtypes was not affected by whether a sample came
from Minia or Cairo. However, 60% of Luminal B
tumors and 65% of basal-like tumors were from Minia,
whereas 81% of unclassified cases were from Cairo (p <
0.001, Table 1). Two-way analysis of variance (ANOVA)
with post hoc comparison revealed no overall associa-
tion to age with different molecular subgroups (Table 2).
Comparison of tumor size, histologic subtype, lymph
node status and proliferation index among molecular
subtypes
Intermediate tumor grade accounted for the majority (>
78%) of each molecular subtype and no great association
of tumor grade to molecular subtype was found (Table
3). Greater than 70% of Luminal A, Luminal B, and
HER2+/ER- tumors were lymph node positive (Table 3).
This differed significantly from unclassified and basal-
like tumors, which only had 50% lymph node positive
cases (p < 0.0001). With regards to tumor size, the only
noticeable distinction occurred in the basal-like group
where all tumors were larger than 2.0 cm (T2 or
greater) (Table 3). Tumors less than 2.0 cm represented
15-24% tumors in the other subtypes (p = 0.0002). The
majority (greater than 65%) of tumors in all subtypes
were of ductal origin. (Table 3, Figure 2). The basal-like
group was also made up of a large number (31.6%) of
medullary tumors, significantly more than in other
molecular subtypes (p < 0.0001) (Table 3). Tumor pro-
liferation was assessed for all tumors by measuring the
percent positive Ki67 tumor nuclei (Figure 3). Unclassi-
fied and the basal-like tumors had the highest Ki67
scores (Figure 3). By definition, Luminal A tumors had
low proliferative indices and Luminal B tumors had
higher Ki67 values compared to Luminal A.
Analysis of surgical procedure among molecular subtypes
Surgical procedures extracted from pathology reports
were consolidated into four groups: biopsy, modified
radical mastectomy (MRM), simple mastectomy (with or
without axillary clearance) and lumpectomy (with or
without axillary clearance). Modified radical mastectomy
Table 2 Distribution of breast cancer molecular subtypes by age and gender
Total Tissue Cases
(N = 203)
Luminal A
(N = 90)
Luminal B
(N = 50)
HER+/ER-
(N = 24)
Unclassified
(N = 16)
Basal-like[CK5/6]
(N = 23)
p-value
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Percent of Tissue Cases 100.0% 44.3% 24.6% 11.8% 7.9% 11.3%
Sex
Female 198 (97.5%) 89 (98.9%) 48 (96.0%) 23 (95.8%) 16 (100.0%) 2 (95.7%)
Male 5 (2.5%) 1 (1.1%) 2 (4.0%) 1 (4.2%) 0 (0.0%) 1 (4.3%)
Age, years
< 30 5 (2.9%) 0 (0.0%) 3 (7.0%) 1 (4.5%) 0 (0.0%) 1 (5.0%)
30-40 23 (13.4%) 11 (14.3%) 5 (11.6%) 3 (13.6%) 0 (0.0%) 4 (20.0%)
41-50 64 (37.2%) 25 (32.5%) 22 (51.2%) 7 (31.8%) 2 (20.0%) 8 (40.0%)
30-50 87 (50.6%) 36 (46.8%) 27 (62.8%) 10 (45.5%) 2 (20.0%) 12 (60.0%)
> 50 80 (46.5%) 41 (53.2%) 13 (30.2%) 11 (50.0%) 8 (80.0%) 7 (35.0%)
Not Available 31 13 7 2.00 6.00 3.00
Mean 51.30 52.31 48.19 51.64 57.10 50.05 0.138
Median 50.00 52.00 48.00 52.50 58.00 46.50
SD 10.78 9.66 11.50 12.20 7.56 12.79
Mean from Cairo 53.4 55.45 48.84 53.40 57.10 49.29
Mean from Minia 49.46 49.95 47.67 50.38 50.46
Age Range 24 - 80 30 - 73 25 - 80 24 - 77 42 - 70 28 - 80
Age Range from Cairo 25 - 73 35 - 73 25 - 65 38 - 72 42 - 70 28 - 70
Age Range from Minia 24 - 80 30 - 70 25 - 80 24 - 77 40 - 80
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was the preferred surgical procedure and was not asso-
ciated to molecular subtype. Interestingly, 89% of biop-
sies and 61% MRMs were performed in Minia, whereas
100% of lumpectomies were performed in Cairo (p <
0.0001, Table 6), where this was the preferred surgical
approach.
Discussion
The Egyptian breast cancer series in our study was con-
sistent with the expected findings of advanced disease at
time of diagnosis compared to that ordinarily seen in
North America and Europe. In spite of a more advanced
disease at presentation, our study indicated that expres-
sion of ER, PR and Her2 resembled that of Western
countries with no differences between urban and rural
centers in Egypt. Furthermore, our data demonstrated
that the majority of cases were classified as Luminal A
(44%), which offers the best prognosis of all the
subytpes.
A recent retrospective analysis of ER status in Egypt
reported greater than two-fold more ER positive tumors
in urban areas compared with rural areas of Egypt but
that overall ER negative tumors were more prominent
in the population [14]. The authors of that study sug-
gested that higher exposure to xenoestrogens in more
urbanized areas could explain the difference [14]. How-
ever, perhaps the discordance between their study and
ours could also be explained by the fact that testing for
ER and PR is not a routine practice in Egypt. This is
witnessed from the lack of ER or PR data in over 60%
of the cases examined by Dey et al (2010) [14,15].
Luminal A tumors are predominant in Asian, white
and post-menopausal African North Americans. Inter-
estingly, Luminal A was also predominant in people of
Sudanese and Tunisian descent [16,17]. A high fre-
quency of the basal-like subtype has been reported in
about 40% of young premenopausal African North
American women [18]; 27% in women of Nigerian and
Senegalese descent [19]; 15% in post-menopausal Afri-
can North American women [18]; 10% in Sudanese [17],
Saudi populations [20] and in white populations [8].
The Her2 subtype has been also associated with aggres-
sive characteristics but along with Luminal B tumors are
generally not associated to ethnicity [19]. In our study,
we had a significant percentage of Luminal B tumors
compared to that previously reported in North
Table 3 Tumor characteristics of breast cancer molecular subtypes in Egypt
Total Tissue Cases
(N = 203)
Luminal A
(N = 90)
Luminal B
(N = 50)
HER+/ER-
(N = 24)
Unclassified
(N = 16)
Basal-like[CK5/6]
(N = 23)
p-value
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Percent of Tissue Cases 100.0% 44.3% 24.6% 11.8% 7.9% 11.3%
Lymph Nodes * *
Positive 74 (70.5%) 33 (71.7%) 21 (77.8%) 11 (78.6%) 4 (50.0%) 5 (50.0%) < 0.0001
Negative 31 (29.5%) 13 (28.3%) 6 (22.2%) 3 (21.4%) 4 (50.0%) 5 (50.0%)
Not Available 98 44 23 10 8 13
Tumor size, cm (T category) * *
≤ 2.0 (T1) 23 (15.1%) 11 (15.9%) 5 (14.7%) 5 (23.8%) 2 (15.4%) 0 (0.0%) * 0.0002
> 2.0-≤5.0 (T2) 111 (73.0%) 51 (73.9%) 26 (76.5%) 13 (61.9%) 8 (61.5%) 13 (86.7%)
> 5 (T3) 18 (11.9%) 7 (10.1%) 3 (8.8%) 3 (14.3%) 3 (23.1%) 2 (13.3%)
Not Available 51 21 16 3 3 8
Histological grade
Low Grade (G1) 1 (0.7%) 1 (1.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.0443
Intermediate Grade (G2) 120 (82.2%) 51 (78.5%) 34 (85.0%) 13 (86.7%) 10 (76.9%) 12 (92.3%)
High Grade (G3) 25 (17.1%) 13 (20.0%) 6 (15.0%) 2 (13.3%) 3 (23.1%) 1 (7.7%)
Not available 57 25 10 9 3 10
Histological Type
Ductal 142 (75.5%) 62 (73.8%) 41 (87.2%) 15 (68.2%) 12 (75.0%) 12 (63.2%) < 0.0001
Lobular 17 (9.0%) 11 (13.1%) 3 (6.4%) 1 (4.5%) 1 (6.3%) 1 (5.3%)
Mixed ductal & lobular 5 (2.7%) 3 (3.6%) 0 (0.0%) 1 (4.5%) 1 (6.3%) 0 (0.0%)
Medullary 17 (9.0%) 3 (3.6%) 2 (4.3%) 4 (18.2%) 2 (12.5%) 6 (31.6%)
Other 7 (3.7%) 5 (6.0%) 1 (2.1%) 1 (4.5%) 0 (0.0%) 0 (0.0%)
Not Available 15 6 3 2 0 4
Asterisk (*) represents groups with statistically significant differences.
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American and European women (24.6% compared with
6-19%). Luminal B tumors are prognostically less favor-
able than Luminal A tumors but still less aggressive
than basal-like tumors [10]. Until recently, most studies
using IHC to assign molecular subtype status to breast
cancer have not used Ki67 to discriminate between
Luminal A and B and rather only used Her2 status [7].
Therefore, that we see an enrichment of Luminal B in
the Egyptian population compared to other studies
could also be due to the fact that other studies have
simply underestimated the frequency of Luminal B
cases. Unclassified tumors vary across populations and
were highest among indigenous Africans and also high
among 43% of breast cancer in Saudi women [19,20].
This tumor subtype is generally associated with more
aggressive phenotypes [19]. In our study cohort this
molecular subtype represented the smallest group.
There were some noticeable differences depending on
whether tumors originated from Minia or Cairo. Minia
and Cairo represent large rural and urban centers
respectively. Minia with a population of 4 mllion is situ-
ated 152 miles south of Cairo on the western bank of
the Nile River in Middle Egypt and represents a large
rural region in Egypt. Minia is a large agricultural and
industrial town and much smaller in size than one of
the world’s largest urban cities, Cairo with nearly 20
million inhabitants. Tumors in Minia were higher grade,
and were significantly more lymph node positive but
surprisingly tumors were not larger in size. In fact there
was a higher frequency of tumors classified as T1 from
Minia. Furthermore, surgical practices differed as well
with none of the lumpectomies performed in Minia.
With regards to molecular subtype, tumors from Minia
represented the majority of Luminal B and basal-like
tumors and also demonstrated significantly fewer
unclassified cases than ones from Cairo. Patient age, his-
tological subtype distribution, hormone receptor fre-
quency and Her2 status did not vary by site of origin.
Although it is not entirely clear why these differences
exist, collectively, they point towards socio-cultural and
biological heterogeneity not accounted for between the
two regions of Egypt. The differences are also likely to be
an indication of inherent differences in medical practice,
which may itself be related to socio-cultural factors, a
dampened degree of modernity and fewer resources
Table 4 Breast cancer characteristics by site of origin
Cairo
(N = 90)
Minia
(N = 113)
p-value
No. (%) No. (%)
Age
Mean 53.4 49.5
Lymph Nodes
Positive 35 (61.4%) 39 (81.3%) 0.0029
Negative 22 (38.6%) 9 (18.8%)
Not Available 33 65
Tumor size, cm (T category)
≤ 2.0 (T1) 5 (6.1%) 18 (25.7%) 0.001
> 2.0-≤5.0 (T2) 66 (80.5%) 45 (64.3%)
> 5 (T3) 11 (13.4%) 7 (10%)
Not Available 8 43
Histologic Grade
Low Grade (G1) 1 (1.4%) 0 (0.0%) < 0.0001
Intermediate Grade (G2) 69 (94.5%) 51 (69.9%)
High Grade (G3) 3 (4.1%) 22 (30.1%)
Not Available 17 40
Proliferative Index (Ki67)
Mean 14.9 15.8
SD 12.3 9.8
Table 5 Frequency of ER, PR and Her2 expression in
Egypt
Total Tissue Cases
(N = 203)
Cairo
(N = 90)
Minia
(N = 113)
p-value
No. (%) No. (%) No. (%)
ER
Positive 132 (65.0%) 58.89% 69.91% 0.138
Negative 71 (35.0%) 41.11% 30.09%
PR
Positive 89 (43.8%) 51.11% 38.05% 0.088
Negative 114 (56.2%) 48.89% 61.95%
Her2
Positive 51 (25.1%) 22.22% 27.43% 0.511
Negative 152 (74.9%) 77.78% 72.57%
Figure 1 Distribution of breast cancer molecular subtypes in
Egypt.
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available in Minia. A recent study examining breast cancer
in Minia found an association of poor survival with mar-
kers of poor prognosis; variable treatment profiles; lack of
screening programs and treatment; lack of education; and
poor literacy rates [21].
It is becoming apparent that breast cancer from women
of African Arab descent differs significantly from people of
Sub-Saharan Africa, suggesting important molecular epi-
demiological differences that need to be understood when
dealing with breast cancer on the African continent. In
addition, the ancestry of the Modern Egyptian could have
important implications. Although this is a topic which
remains controversial, two studies examined Y chromo-
some haplotypes in Egypt and 45 informative biallelic mar-
kers, as well as, 10 microsatellite loci on the
nonrecombining region of the Y chromosome (NRY)
[22,23]. The most frequent haplotype was haplotype V
which is a characteristic Arab haplotype [22]. This is com-
pared to haplotype IV which is prevalent in sub-Saharan
Africa and found at a much lower frequency in Egypt [22].
Egypt’s NRY frequency distributions appear to be much
more similar to those of the Middle East than to any sub-
Saharan African population [23]. These studies suggest a
much larger Eurasian genetic component thus explaining
in part the different molecular profile of breast cancer
from other Sub-Saharan African nations.
The general lack of association to clinical tumor features
has been reported in other studies [17,19] and could mean
that intrinsic subtype is predetermined or that other eth-
nic-specific, not yet understood, biological mechanisms
are responsible. The association between molecular sub-
type and tumor proliferation in our study is consistent
with the literature, which indicates that basal-like and
unclassified tumors have higher proliferation indices com-
pared to Luminal A tumors [7]. Luminal B tumors by defi-
nition had higher proliferation compared with Luminal A
tumors [7]. Although basal-like tumors consisted of a
higher percentage of medullary tumors, studies have
shown that all medullary tumors are basal-like [24]. In
addition, medullary tumors were more frequently diag-
nosed in the Egyptian cohort (9%), whereas they comprise
less than 2% of breast cancers in Western nations [25]. It
Figure 2 Distribution of breast cancer histological subtypes in relation to molecular subtype.
Figure 3 Ki67 proliferative index of breast cancer molecular
subtypes in Egypt.
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is not clear why these differences exist and could be
related to differences in diagnostic criteria. Whether this
could also be due to a higher frequency of BRCA1 muta-
tions, for which this histological subtype has been asso-
ciated [26], diagnostic criteria or other causes still needs to
be determined.
A recent study demonstrated that while African
Americans had higher breast-cancer specific mortality
than whites, the effect of race was only statistically sig-
nificant among women with luminal A breast cancer
[10]. However, mortality for patients with basal-like
breast cancer was higher among whites, suggesting that
basal-like breast cancer is not an inherently more
aggressive disease in African American women [10].
This study is highly relevant to ours and supports the
notion that poor outcomes seen in Egyptian women
compared with Western women need not be explained
by a higher prevalence in the basal-like subtype. Given
that the distribution of molecular subtypes are similar
among Arabs and Western Caucasian women, the dif-
ference in outcomes between the two populations may
not have biological underpinnings. Instead, for women
of Egypt, our data point towards the importance of early
diagnosis, therapy received (or not received), nutrition,
co-morbidity, overall general health, or potential other
causes. Particularly relevant to developing and under-
served communities, socioeconomic factors, availability
of resources, access to care, disease awareness, and cul-
tural stigmas are important contributing factors [15,27].
Nevertheless, performing gene expression profiling as a
next step could help identify additional Luminal-asso-
ciated genes unique to the Egyptian population.
Conclusions
While the breast cancer disparity of this population is
unfortunate, the results of our study are optimistic and
provide an important opportunity to intervene. It is not
unrealistic to conceive that “simple” and relatively inexpen-
sive measures of increasing awareness and improving early
detection alone could improve survival rates dramatically.
There is ample evidence due to comprehensive clinical
trials that early detection by screening along with timely
and effective treatments is tightly associated with improve-
ments in breast cancer survival in the industrialized world
[16]. Factoring in measures to implement mandatory ER
and PR stratification of patients with national standardized
IHC protocols and proper training, whilst increasing efforts
to bolster the use of hormonal therapy has the potential of
matching breast cancer survival rates to that of the United
States. Evidence for this comes from the fact that while
minority women in the United States are more likely to
present with advanced disease and have higher mortality
rates than Caucasian women, white women and black
women who present with similar stage of disease and
receive similar treatments have similar outcomes [16].
Although there are clear and hopeful signs that pro-
grams to increase awareness and education are beginning
to emerge in Egypt thanks to organizations like The Breast
Cancer Foundation of Egypt, The Suzanne Mubarak
Regional Centre for Women’s Health and Development,
The Susan G. Komen for the Cure, and the US Agency for
International Development (US-AID), more is needed in
the way of patient outreach, resources, and improving
training for physicians throughout. This study will help
lead to new and needed bio-repository efforts in Egypt and
other nations in Africa, which will facilitate further
research and help to determine other bio-ethnic specific
variability. Finally, with such few resources available in
Africa we need to understand and report biological differ-
ences in order to proceed in the most efficient and effec-
tive manner. The impact of our study doesn’t stem from
the identification of novel biomarkers or therapeutics, but
from its utility; there is a real opportunity to help save the
lives of many in Egypt by simply improving rates of early
detection, and utilizing a set of already known prognostic
and therapeutic markers.
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Table 6 Types of surgery performed in Egypt
Cairo, Egypt (N = 90) Minia, Egypt (N = 113) p-value
No. (%) No. (%)
Surgery
Biopsy 6 (6.67%) 48 (46.6%) < 0.0001
Modified Radical Mastectomy 32 (35.56%) 51 (49.5%)
Mastectomy ± axillary clearance 9 (10.00%) 4 (3.9%)
Lumpectomy ± axillary clearance 43 (47.78%) 0 (0.0%)
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